Orbiepharm Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 50

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 8

Orbiepharm General Information

Description

Developer of pharmaceuticals and diagnostic products designed for animal health. The company's products focus on pet health, including medical diseases, chronic diseases, and geriatric diseases, and the company is the only pet medicine and health industry chain group enterprise with R&D, production, sales, and terminal hospitals in China now, enabling the animals to have more efficient diagnosis and treatment.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 203, Haohai Building
  • No. 7 Shangdi 5th Street, Haidian District
  • Beijing, 100085
  • China
+86 010
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • Room 203, Haohai Building
  • No. 7 Shangdi 5th Street, Haidian District
  • Beijing, 100085
  • China
+86 010

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Orbiepharm Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 27-Jul-2022 Completed Generating Revenue
3. Later Stage VC 12-Nov-2018 Completed Generating Revenue
2. Later Stage VC 16-Mar-2016 Completed Generating Revenue
1. Early Stage VC 01-Jan-2013 Completed Generating Revenue
To view Orbiepharm’s complete valuation and funding history, request access »

Orbiepharm Patents

Orbiepharm Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2013026357-A1 Preparation method of imidazole derivatives Inactive 25-Aug-2011
EP-2636672-A1 Imidazole derivatives and preparation method and use thereof Active 02-Nov-2010
EP-2636672-A4 Imidazole derivatives and preparation method and use thereof Active 02-Nov-2010
EP-2636672-B1 Imidazole derivatives and preparation method and use thereof Active 02-Nov-2010
US-20130225638-A1 Imidazole derivatives and preparation method and use thereof Active 02-Nov-2010 C07D401/04
To view Orbiepharm’s complete patent history, request access »

Orbiepharm Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Orbiepharm Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Beijing Jinhuitong Investment Fund Management Growth/Expansion Minority
Lucion Venture Capital Venture Capital Minority
Shandong High-tech Venture Capital Venture Capital Minority
CCB International Trade (Xiamen) Private Equity Fund Management Growth/Expansion Minority
China Cinda Asset Management Corporation Minority
You’re viewing 5 of 8 investors. Get the full list »

Orbiepharm FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process